Kimelman & Baird LLC Reduces Position in Teleflex Incorporated (NYSE:TFX)

Kimelman & Baird LLC cut its position in Teleflex Incorporated (NYSE:TFX) by 34.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 65,260 shares of the medical technology company’s stock after selling 34,267 shares during the period. Kimelman & Baird LLC owned 0.14% of Teleflex worth $11,615,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Janus Henderson Group PLC increased its position in shares of Teleflex by 2.8% in the 3rd quarter. Janus Henderson Group PLC now owns 5,376,452 shares of the medical technology company’s stock valued at $1,329,704,000 after purchasing an additional 147,147 shares during the last quarter. State Street Corp increased its position in shares of Teleflex by 1.0% in the 3rd quarter. State Street Corp now owns 2,057,080 shares of the medical technology company’s stock valued at $508,757,000 after purchasing an additional 21,291 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Teleflex by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,130,560 shares of the medical technology company’s stock valued at $278,676,000 after purchasing an additional 5,746 shares during the last quarter. Cooke & Bieler LP grew its position in shares of Teleflex by 22.1% in the 4th quarter. Cooke & Bieler LP now owns 1,078,557 shares of the medical technology company’s stock valued at $191,962,000 after buying an additional 195,150 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in shares of Teleflex by 0.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 427,579 shares of the medical technology company’s stock valued at $105,749,000 after buying an additional 1,884 shares during the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex Stock Up 1.1 %

TFX stock opened at $137.79 on Monday. Teleflex Incorporated has a one year low of $128.55 and a one year high of $249.90. The stock has a market capitalization of $6.39 billion, a PE ratio of 27.39, a price-to-earnings-growth ratio of 1.73 and a beta of 1.21. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. The company has a fifty day moving average of $166.99 and a 200-day moving average of $197.37.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, topping the consensus estimate of $3.86 by $0.03. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The company had revenue of $795.40 million during the quarter, compared to analysts’ expectations of $813.24 million. As a group, analysts expect that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, March 17th. Stockholders of record on Friday, March 7th will be paid a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.99%. The ex-dividend date of this dividend is Friday, March 7th. Teleflex’s dividend payout ratio (DPR) is presently 95.77%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Piper Sandler reaffirmed a “neutral” rating and issued a $140.00 target price (down from $255.00) on shares of Teleflex in a research report on Friday, February 28th. Morgan Stanley dropped their target price on shares of Teleflex from $275.00 to $191.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Citizens Jmp downgraded shares of Teleflex from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 27th. Needham & Company LLC reaffirmed a “hold” rating on shares of Teleflex in a research report on Wednesday, March 12th. Finally, Raymond James downgraded shares of Teleflex from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $182.63.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.